all the information, none of the junk | biotech • healthcare • life sciences

Former Bristol Exec Albright Named CSO of Editas

Cambridge, MA-based gene editing company Editas Medicine (NASDAQ: EDIT) has named Charles Albright its chief scientific officer. Albright was most recently the VP of genetically defined diseases and genomics at Bristol-Myers Squibb, and held positions at Incyte and DuPont Pharmaceuticals before that.

Ben Fidler is Xconomy's Deputy Editor, Biotechnology. You can e-mail him at bfidler@xconomy.com Follow @benthefidler